| Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology MS Tallman, ES Wang, JK Altman, FR Appelbaum, VR Bhatt, D Bixby, ... Journal of the National Comprehensive Cancer Network 17 (6), 721-749, 2019 | 468 | 2019 |
| Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology MR O'Donnell, MS Tallman, CN Abboud, JK Altman, FR Appelbaum, ... Journal of the National Comprehensive Cancer Network 15 (7), 926-957, 2017 | 448 | 2017 |
| NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018 MH Shah, WS Goldner, TR Halfdanarson, E Bergsland, JD Berlin, ... Journal of the National Comprehensive Cancer Network 16 (6), 693-702, 2018 | 351 | 2018 |
| NCCN guidelines insights: acute myeloid leukemia, version 2.2021: featured updates to the NCCN guidelines DA Pollyea, D Bixby, A Perl, VR Bhatt, JK Altman, FR Appelbaum, ... Journal of the National Comprehensive Cancer Network 19 (1), 16-27, 2021 | 294 | 2021 |
| NCCN guidelines insights: genetic/familial high-risk assessment: colorectal, version 2.2019: featured updates to the NCCN guidelines S Gupta, D Provenzale, X Llor, AL Halverson, W Grady, DC Chung, ... Journal of the National Comprehensive Cancer Network 17 (9), 1032-1041, 2019 | 251 | 2019 |
| Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN clinical practice guidelines in oncology P Brown, H Inaba, C Annesley, J Beck, S Colace, M Dallas, K DeSantes, ... Journal of the National Comprehensive Cancer Network 18 (1), 81-112, 2020 | 208 | 2020 |
| NCCN guidelines insights: colorectal cancer screening, version 1.2018 D Provenzale, S Gupta, DJ Ahnen, AJ Markowitz, DC Chung, RJ Mayer, ... Journal of the National Comprehensive Cancer Network 16 (8), 939-949, 2018 | 164 | 2018 |
| Hodgkin lymphoma, version 2.2020, NCCN clinical practice guidelines in oncology RT Hoppe, RH Advani, WZ Ai, RF Ambinder, P Armand, CM Bello, ... Journal of the National Comprehensive Cancer Network 18 (6), 755-781, 2020 | 152 | 2020 |
| NCCN guidelines insights: genetic/familial high-risk assessment: colorectal, version 3.2017 S Gupta, D Provenzale, SE Regenbogen, H Hampel, TP Slavin, MJ Hall, ... Journal of the National Comprehensive Cancer Network 15 (12), 1465-1475, 2017 | 147 | 2017 |
| NCCN guidelines insights: colorectal cancer screening, version 2.2020: featured updates to the NCCN guidelines D Provenzale, RM Ness, X Llor, JM Weiss, B Abbadessa, G Cooper, ... Journal of the National Comprehensive Cancer Network 18 (10), 1312-1320, 2020 | 133 | 2020 |
| The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor … BM Wittmann, K Fujinaga, H Deng, N Ogba, MM Montano Oncogene 24 (36), 5576-5588, 2005 | 98 | 2005 |
| NCCN guidelines® insights: palliative care, version 2.2021: featured updates to the NCCN guidelines M Dans, JS Kutner, R Agarwal, JN Baker, JR Bauman, AC Beck, ... Journal of the National Comprehensive Cancer Network 19 (7), 780-788, 2021 | 97 | 2021 |
| Hodgkin lymphoma version 1.2017, NCCN clinical practice guidelines in oncology RT Hoppe, RH Advani, WZ Ai, RF Ambinder, P Aoun, CM Bello, ... Journal of the National Comprehensive Cancer Network 15 (5), 608-638, 2017 | 94 | 2017 |
| Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells N Ogba, NG Manning, BS Bliesner, SK Ambler, JM Haughian, MP Pinto, ... Breast Cancer Research 16, 1-14, 2014 | 77 | 2014 |
| NCCN guidelines insights: acute lymphoblastic leukemia, version 1.2017 PA Brown, B Shah, A Fathi, M Wieduwilt, A Advani, P Aoun, SK Barta, ... Journal of the National Comprehensive Cancer Network 15 (9), 1091-1102, 2017 | 76 | 2017 |
| NCCN guidelines insights: Hodgkin lymphoma, version 1.2018 RT Hoppe, RH Advani, WZ Ai, RF Ambinder, P Aoun, P Armand, CM Bello, ... Journal of the National Comprehensive Cancer Network 16 (3), 245-254, 2018 | 72 | 2018 |
| NCCN guidelines insights: acute lymphoblastic leukemia, Version 1.2019: featured updates to the NCCN guidelines PA Brown, M Wieduwilt, A Logan, DJ DeAngelo, ES Wang, A Fathi, ... Journal of the National Comprehensive Cancer Network 17 (5), 414-423, 2019 | 66 | 2019 |
| HEXIM1 regulates 17β-estradiol/estrogen receptor-α–mediated expression of cyclin d1 in mammary cells via modulation of P-TEFb N Ogba, LJ Chaplin, YQ Doughman, K Fujinaga, MM Montano Cancer Research 68 (17), 7015-7024, 2008 | 43 | 2008 |
| HEXIM1 modulates vascular endothelial growth factor expression and function in breast epithelial cells and mammary gland N Ogba, YQ Doughman, LJ Chaplin, Y Hu, M Gargesha, M Watanabe, ... Oncogene 29 (25), 3639-3649, 2010 | 27 | 2010 |
| HEXIM1 is a critical determinant of the response to tamoxifen W Ketchart, N Ogba, A Kresak, JM Albert, JJ Pink, MM Montano Oncogene 30 (33), 3563-3569, 2011 | 26 | 2011 |